Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if dalteparin can lower the risk of VTE
occurring in the legs and lungs. This will be tested in patients with pancreatic cancer who
are going to receive chemotherapy. Some patients will receive dalteparin and some will
receive no study drug.
The safety of dalteparin will also be studied.